GW-501516 (GW-1516 or GSK-516) is a drug that acts as a PPAR modulator. GW-501516 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in animal studies.
1.It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease.
2.GW501516 could be used by athletes and bodybuilders as an ergogenic performance enhancing drug.